Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGT4255 in Advanced Solid Tumors With ERBB2 Alterations or HER2 Overexpression
NCT07361562Phase 1Recruiting
- Sponsor
- Cogent Biosciences
- Start
- Dec 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CGT4255 in solid tumor, non-small cell lung cancer (NSCLC) and breast cancer (3 arms), sponsored by Cogent Biosciences. Primary endpoints: Incidence and grade of Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 months and Overall Response Rate at 6 months. Started Dec 2025; status: recruiting.
02
Drugs
CGT4255
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancer
Beyond the preview
Go deeper on NCT07361562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361562.